Quince Therapeutics, Inc. (IRLA)
IRulya Therapeutics is a clinical-stage biopharmaceutical company developing LAM-001, an inhaled formulation of rapamycin, for pulmonary diseases. Its clinical programs target pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome after lung transplant, and sarcoidosis-associated pulmonary hypertension.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
IRulya Therapeutics Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 1.02M shares outstanding
No company description available.
Leadership
Dirk Thye
Chief Executive Officer, Chief Medical Officer & Director
Charles S. Ryan
President
Brendan Hannah
Chief Business Officer, Chief Operating Officer, Chief Compliance Officer and Principal Financial & Accounting Officer
Brigette Roberts
CEO, Principal Executive Officer & Director
Employees
--
Country
--
Sector
Healthcare
Website
--
| Name | Shares | % | Source |
|---|---|---|---|
Nantahala Capital Management, LLC · joint filing· may incl. warrants· filed May 2026 | 4.5M | 7.5% as filed | 13G |
Perceptive Advisors LLC · joint filing· may incl. warrants· filed Oct 2026 | 912.9K | 8.4% as filed | 13G |
James B. Tananbaum · joint filing· may incl. warrants· filed Oct 2026 | 652.0K | 6.0% as filed | 13G |
 Hannah Brendan CBO, COO & CCO | 361.8K | 35.6% | FORM 4 |
 Thye Dirk CEO and CMO, Director | 255.0K | 25.1% | FORM 4 |
 Ryan Charles S. President | 130.0K | 12.8% | FORM 4 |
Ikarian Capital, LLC | 72.3K | 7.1% | 13F |
MILLENNIUM MANAGEMENT LLC | 70.8K | 7.0% | 13F |
BALYASNY ASSET MANAGEMENT L.P. | 70.0K | 6.9% | 13F |
Squadron Capital Management LLC | 40.4K | 4.0% | 13F |
Insiders
- Hannah BrendanCBO, COO & CCO
- Thye DirkCEO and CMO, Director
- Ryan Charles S.President
- Benatti LucaDirector
based on 1.02M shares outstanding
30d Avg
99.37K
60d Avg
99.37K
90d Avg
99.37K